Using NHANES data, researchers estimated the prevalence of chronic axial pain, inflammatory back pain, axial spondyloarthritis, and peripheral arthritis in inflammatory bowel disease.
Oswestry Disability Index score and secondary outcomes favor early PT versus usual care at four weeks
The FDA has approved ReActiv8® (Mainstay Medical), an implantable neurostimulation system, for the treatment of intractable chronic low back.
A review of 12 studies found small improvements in pain levels and function after 3 to 6 months.
Patients who took NSAIDs were also 2.5 times more likely to suffer gastrointestinal side effects.
This method helps block pain signals better than low-frequency treatments for chronic back and leg pain.
